POSTER PRESENTATION

Open Access

A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study)

Andrea Wang-Gillam¹, Vincent Picozzi², Todd Crocenzi³, Michael Morse⁴, Herbert Zeh⁵, Robert Fine⁶, Aimee Murphy⁷, Justin Skoble⁷, Edward Lemmens⁷, Sandy Ferber⁷, Allan Rosen⁷, John Grous⁷, Thomas W Dubensky⁷, Dirk Brockstedt^{7*}, Elizabeth Jaffee⁸, Dung Le⁸

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

Background

A heterologous prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing promise in patients with metastatic pancreatic adenocarcinoma (PDA). GVAX is composed of lethally-irradiated, allogeneic pancreatic cancer cells modified to express GM-CSF and induces a broad response against multiple tumor antigens. GVAX is given with low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated *Listeria monocytogenes* engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and is unique in its capacity to stimulate both innate and adaptive immunity by activating T cells and NK cells. In a recently completed Phase II study, the CY/GVAX plus CRS-207 combination resulted in statistically-significant improvement of overall survival (OS) compared to CY/GVAX alone (Le, GI ASCO 2014).

Methods

This is a Phase IIb study comparing CY/GVAX and CRS-207 to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic PDA. Subjects will be enrolled in two cohorts: 150 subjects into a primary cohort of patients with at least two prior treatment regimens for

metastatic disease (3rd+ line) and 90 subjects into an exploratory cohort of patients with only one prior treatment regimen for metastatic disease (2nd line). Subjects will be randomized in a 1:1:1 ratio to receive either 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm A), 6 doses of CRS-207 (Arm B) or physician's choice of select single-agent chemotherapy (Arm C). The primary objective is to compare OS in the primary cohort between Arms A and C. Secondary/exploratory objectives include: comparison of OS in both primary and exploratory cohorts between all treatment arms, assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of *Lm*- and mesothelin-specific T cell and other immunological responses with OS, progression-free survival and best overall response. (Sponsor: Aduro BioTech, Inc.; NCT02004262).

Authors' details

¹Washington University School of Medicine in St. Louis, St. Louis, MO, USA. ²Virginia Mason Medical Center, Seattle, WA, USA. ³Earle A. Chiles Research Institute, Portland, OR, USA. ⁴Duke University Medical Center, Durham, NC, USA. ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ⁶Columbia University, New York, NY, USA. ⁷Aduro BioTech, Inc., Berkeley, CA, USA. ⁸The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

Published: 6 November 2014

⁷Aduro BioTech, Inc., Berkeley, CA, USA

Full list of author information is available at the end of the article

doi:10.1186/2051-1426-2-S3-P68

Cite this article as: Wang-Gillam *et al.*: A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study). *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P68.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit